Model for End-Stage Liver Disease (MELD) exception guidelines: Results and recommendations from the MELD exception study group and conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula

Liver Transplantation

Volumn 12, Issue 12 SUPPL. 3, 2006, Pages

  Freeman Jr , Richard B ^a   Gish, Robert G ^b   Harper, Ann ^c   Davis, Gary L ^d   Vierling, John ^e   Lieblein, Leslie ^c   Klintmalm, Goran ^d   Blazek, Jamie ^f   Hunter, Robert ^c   Punch, Jeffrey ^g  

^a TUFTS MEDICAL CENTER   (United States)

^b CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^c UNITED NETWORK FOR ORGAN SHARING   (United States)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Ochsner Multi Organ Transplant Center   (United States)

^g UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ASCITES; BILE DUCT CARCINOMA; BUDD CHIARI SYNDROME; CHOLANGITIS; CYSTIC FIBROSIS; EVIDENCE BASED MEDICINE; FAMILIAL AMYLOID POLYNEUROPATHY; GASTROINTESTINAL HEMORRHAGE; GRAFT DYSFUNCTION; HEPATIC ENCEPHALOPATHY; HEPATOPULMONARY SYNDROME; HUMAN; LIVER FAILURE; LIVER POLYCYSTIC DISEASE; LIVER TRANSPLANTATION; LIVER TUMOR; MATHEMATICAL MODEL; METABOLIC DISORDER; OXALOSIS 1; PATIENT SELECTION; PORTAL HYPERTENSION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; PULMONARY HYPERTENSION; RENDU OSLER WEBER DISEASE; SMALL FOR SIZE SYNDROME;

ASCITES; BILE DUCT NEOPLASMS; CYSTIC FIBROSIS; HEPATIC ENCEPHALOPATHY; HUMANS; HYPEROXALURIA, PRIMARY; LIVER FAILURE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MODELS, BIOLOGICAL; PRACTICE GUIDELINES AS TOPIC; SEVERITY OF ILLNESS INDEX; TISSUE AND ORGAN PROCUREMENT;

EID: 33845491491     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.20979     Document Type: Article

References (27)

1. Freeman RB, Weisner RH, Harper A, McDairmid SV, Lake J, Edwards EB, et al. The New Liver Allocation System: moving towards evidence-based transplantation policy. Liver Transpl 2002;8:851-858.
2. Mazzaferro V, Regalio E, Doci R, Andreola S, Pulvirenti A, Bozzeti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-699.
3. Wiesner RH, Freeman RB, Mulligan DC. Liver transplantation for hepatocellular cancer: the impact of the MELD allocation policy. Gastroenterology 2004;127:S261-S267.
4. Cheng SJ, Freeman RB, Wong JB. Predicting the probability of progression free survival in patients with small hepatocellular carcinoma. Liver Transpl 2002;8:323-328.
5. Yao FY, Bass NM, Nikolai B, Davern TJ, Kerlan R, Wu V, et al. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl 2002;8:873-883.
6. Freeman RB, Edwards EB, Harper AM. Comparison of liver transplant waiting list removal rates among patients with chronic and malignant liver diseases. Am J Transpl 2006;6:1416-1421.
7. Organ Procurement and Transplantation Network. Policies. Available at: http://www.optn.org/policiesAndBylaws/policies.asp. Accessed September 5, 2006.
8. Biggins SW, Colquhoun S, Gish RG, Runyon BA. Model for End-Stage Liver Disease (MELD) exception for ascites. Liver Transpl 2006. In press.
9. Biggins SW, Rodriguez HJ, Bacchetti P, Bass NM, Roberts JP, Terrault NA. Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology 2005;41: 32-39.
10. Ham J, Gish RG, Mullen K. Model for End-Stage Liver Disease (MELD) exception for hepatic encephalopathy. Liver Transpl 2006;12:S102-S104.
11. Arrazola L, Moonka D, Gish RG, Everson GT. Model for End-Stage Liver Disease (MELD) exception for polycystic liver disease. Liver Transpl 2006;12:S110-S111.
12. Sheiner P, Gish RG, Sanyal A. Model for End-Stage Liver Disease (MELD) exception for portal hypertensive GI bleeding. Liver Transpl 2006;12:S112-S113.
13. Fallon MB, Mulligan DC, Gish RG, Krowka MJ. Model for End-Stage Liver Disease (MELD) exception for hepatopulmonary syndrome. Liver Transpl 2006;12:S105-S107.
14. Krowka MJ, Fallon MB, Mulligan DC, Gish RG. Model for End-Stage Liver Disease (MELD) except on for portopulmonary hypertension. Liver Transpl 2006;12:S114-S116.
15. Ramsay MA. Perioperative mortality in patients with portupulmonary hypertension undergoing liver transplantation. Liver Transpl 2000;6:451-452.
16. Washburn WK, Gish RG, Kamath PS. Model for End-Stage Liver Disease (MELD) exception for Budd-Chiari syndrome. Liver Transpl 2006;12:S93-S94.
17. Washburn WK, Gish RG. Model for End-Stage Liver Disease (MELD) exception for severe pruritis. Liver Transpl 2006;12:S119.
18. Horslen S, Gish RG, McDonald R. Model for End-Stage Liver Disease (MELD) exception for primary hyperoxaluria. Liver Transpl 2006;12:S117-S118.
19. Pomfret E, Gish RG, Brandhagen D. Model for End-Stage Liver Disease (MELD) exception for familial amyloidotic polyneuropathy. Liver Transpl 2006;12:S100-S101.
20. Horslen S, Sweet S, Gish RG, Shepherd R. Model for End-Stage Liver Disease (MELD) Exception for cystic fibrosis. Liver Transpl 2006;12:S98-S99.
21. Gores GJ, Gish RG, Sudan D, Rosen CB. Model for End-Stage Liver Disease (MELD) exception fo cholangocarcinoma or biliary dyspepsia. Liver Transpl 2006;12:S95-S97.
22. Gores GJ, Gish RG, Shrestha R, Wiesner RH. Model for End-Stage Liver Disease (MELD) exception for bacterial cholangitis. Liver Transpl 2006;12:S91-S92.
23. Punch J, Gish RG. Model for End-Stage Liver Disease (MELD) exception for uncommon hepatic tumors. Liver Transpl 2006;12:S122-S123.
24. McDiarmid SV, Gish RG, Horslen S, Mazariegos GV. Model for End-Stage Liver Disease (MELD) exception for unusual metabolic liver diseases. Liver Transpl 2006;12:S124-S127.
25. Sheiner P, Belghiti J, Gish RG, Miller C. Model for End-Stage Liver Disease (MELD) exception for small-for-size syndrome. Liver Transpl 2006;12:S120-S121.
26. Freeman RB. Mortality risk versus other endpoints: who should come first on the liver transplant waiting list? Liver Transpl 2004;10:675-677.
27. Freeman RB. Model for End-Stage Liver Disease (MELD) and quality of life. Liver Transpl 2005:11:134-136.